# bioAffinity Technologies, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/bioAffinity Technologies, Inc.). ## Overview bioAffinity Technologies, Inc. is a U.S.-based life sciences company that develops noninvasive diagnostic tests for early-stage lung cancer and other lung diseases. Through its clinical pathology operations, it also provides anatomic and clinical pathology services, including patient testing, histology services, and medical director services. ## Products & services • CyPath® Lung noninvasive lung cancer diagnostic test • Anatomic and clinical pathology services • Histology service fees • Medical director services • Patient testing and laboratory reporting - **Diagnostic tests** (20%) — Noninvasive tests for detecting early-stage lung cancer and other lung diseases, including CyPath® Lung. - **Patient service fees** (65%) — Clinical pathology services billed for patient testing and related laboratory work. - **Histology services** (10%) — Tissue processing and histology services provided to pathology customers and labs. - **Medical director services** (5%) — Physician oversight and medical director support for pathology and laboratory operations. - CyPath® Lung noninvasive lung cancer diagnostic test - Anatomic and clinical pathology services - Histology service fees - Medical director services - Patient testing and laboratory reporting ## Customers The company serves patients through physician-ordered pathology and diagnostic testing, with third-party payors such as insurance companies and governmental payors typically responsible for most of the fee. It also sells services to contract research organizations, hospitals, and independent laboratories that need pathology, histology, or medical director support. - **Patients** (primary) — Individuals undergoing physician-ordered pathology and CyPath® Lung testing; they are the end customer for most service revenue. - **Third-party payors** (primary) — Insurance companies and governmental payors that reimburse patient service fees and determine collectible revenue. - **Hospitals** (secondary) — Hospital customers that purchase pathology, histology, and related laboratory services. - **Independent laboratories** (secondary) — Labs that outsource pathology-related services or require medical director support. - **Contract research organizations** (secondary) — CROs that use the company for specialized pathology and research-related laboratory services. - Patients receiving physician-ordered pathology and diagnostic testing - Third-party payors that reimburse most patient service fees - Contract research organizations needing laboratory support - Hospitals using pathology and histology services - Independent laboratories buying medical director and lab services ## Geography bioAffinity Technologies is headquartered in the United States and its commercial and laboratory activities are centered there. The company has disclosed commercialization of CyPath® Lung in Texas, with expansion into the Mid-Atlantic region and the Veterans Administration, while development and regulatory ambitions also reference broader U.S. and international markets. - United States is the core operating and commercial market - CyPath® Lung has been marketed in Texas - Commercial expansion has included the Mid-Atlantic region - Veterans Administration is a disclosed channel for testing - International regulatory references include Europe and China ## Strategy The company’s strategy is to expand commercialization of CyPath® Lung while continuing to develop additional diagnostic tests and related products. It also seeks financing and collaborative or licensing arrangements to support clinical development, regulatory progress, and broader market access. - **Commercialize CyPath® Lung** (short-term) — The test is the company’s core diagnostic product and a key path to scalable revenue. - **Develop additional diagnostics** (medium-term) — A broader product pipeline can diversify revenue beyond a single lung cancer test. - **Secure external funding and partnerships** (short-term) — Development, trials, and commercialization require capital and strategic support. - Expand commercialization of CyPath® Lung - Develop additional diagnostic tests for lung disease - Advance products through clinical trials and regulatory review - Pursue financing, collaborations, and licensing deals - Broaden laboratory revenue from pathology services ## Risks The company depends on external financing and has a limited operating history, so execution risk is elevated if commercialization or capital raising slows. It also faces intense competition in diagnostics and biotechnology, plus regulatory and reimbursement risk because test adoption depends on validation, payer coverage, and clinical acceptance. - **Financing dependence** [critical] — Operations and development require external capital if operating cash flow is insufficient. - **Going-concern and liquidity pressure** [critical] — The company has disclosed substantial doubt about its ability to continue without additional funding. - **Regulatory and clinical validation risk** [high] — Diagnostic products must clear clinical, laboratory, and regulatory hurdles before broad adoption. - **Competition from larger diagnostics and biotech firms** [high] — Competitors may have greater resources, faster approvals, or better commercialization reach. - **Reimbursement and credit loss risk** [medium] — Patient service revenue depends on payor coverage, capped pricing, and collectability. - Needs additional capital to fund operations and development - Limited operating history makes execution harder to assess - Diagnostic and biotech competition is intense and fast-moving - Regulatory approval and validation remain uncertain - Reimbursement and collection rates affect patient revenue ## Accounting Revenue recognition is driven by completion of testing or services rendered, while patient service revenue is reduced by allowances for credit losses and payor adjustments. Investors should also watch stock-based compensation, lease accounting for lab equipment, and impairment testing for goodwill and intangible assets because these estimates can materially affect reported results. - **Patient fee revenue and credit losses** — Affects net revenue and accounts receivable - **Revenue recognition timing** — Affects quarterly comparability - **Lease accounting** — Affects lease liabilities and depreciation/interest expense - **Stock-based compensation** — Affects operating expenses and equity dilution - **Goodwill and intangible assets** — Could create non-cash impairment charges - Patient revenue is net of payor discounts and credit loss allowances - Revenue is recognized when testing is completed or services are rendered - CECL estimates affect accounts receivable and net patient revenue - ASC 842 lease accounting affects lab equipment and related liabilities - Stock-based compensation can materially affect operating expenses --- *Last updated: 2026-04-29T05:12:06.990403+00:00*